Roseola medical therapy: Difference between revisions
Jump to navigation
Jump to search
Category |
m Bot: Removing from Primary care |
||
| Line 14: | Line 14: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Latest revision as of 00:03, 30 July 2020
|
Roseola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Roseola medical therapy On the Web |
|
American Roentgen Ray Society Images of Roseola medical therapy |
|
Risk calculators and risk factors for Roseola medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]
Overview
There is no treatment for roseola, it is a self limiting disease that resolves on its own without any medical intervention but antipyretics can be used as a supportive therapy in cases of high fever.[1]
Medical therapy
The mainstay of therapy for roseola is supportive as HHV 6 typically causes a benign, self limited illness in infants and antiviral therapy is not indicated.
- Supportive therapy for roseola includes antipyretics such as acetaminophen if associated with discomfort.
- Intravenous foscarnet and ganciclovir are proposed as first line treatment for HHV 6 encephalitis for 3 to 4 weeks.
References
- ↑ Agut H, Bonnafous P, Gautheret-Dejean A (2015). "Laboratory and clinical aspects of human herpesvirus 6 infections". Clin Microbiol Rev. 28 (2): 313–35. doi:10.1128/CMR.00122-14. PMC 4402955. PMID 25762531.